These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 21062104)

  • 21. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study
.
    Han MH; Nam JH; Noh E; Lee EK
    Int J Clin Pharmacol Ther; 2019 Nov; 57(11):531-541. PubMed ID: 31397273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
    Pelletier JP; Martel-Pelletier J; Rannou F; Cooper C
    Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S22-7. PubMed ID: 26806184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?
    Perić A; Toskić-Radojičić M; Dobrić S; Damjanov N; Miljković B; Antunović M; Vezmar S
    J Eval Clin Pract; 2010 Dec; 16(6):1090-5. PubMed ID: 20662999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria.
    Hammoumraoui N; Kherraf SA; Mould-Quevedo J; Ismail TA
    J Health Econ Outcomes Res; 2013; 1(2):184-199. PubMed ID: 37662022
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.
    van Staa TP; Leufkens HG; Zhang B; Smeeth L
    PLoS Med; 2009 Dec; 6(12):e1000194. PubMed ID: 19997499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis.
    Kamath CC; Kremers HM; Vanness DJ; O'Fallon WM; Cabanela RL; Gabriel SE
    Value Health; 2003; 6(2):144-57. PubMed ID: 12641865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic model of long-term use of celecoxib in patients with osteoarthritis.
    Loyd M; Rublee D; Jacobs P
    BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
    Katz JN; Smith SR; Collins JE; Solomon DH; Jordan JM; Hunter DJ; Suter LG; Yelin E; Paltiel AD; Losina E
    Osteoarthritis Cartilage; 2016 Mar; 24(3):409-18. PubMed ID: 26525846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
    Johnell K; Fastbom J
    Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.
    Jarupongprapa S; Ussavasodhi P; Katchamart W
    J Gastroenterol; 2013 Jul; 48(7):830-8. PubMed ID: 23208017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.
    Schnitzer TJ
    Clin Ther; 2001 Mar; 23(3):313-326; discussion 311-2. PubMed ID: 11318071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia.
    Nasef SA; Shaaban AA; Mould-Quevedo J; Ismail TA
    Health Econ Rev; 2015 Dec; 5(1):53. PubMed ID: 26061682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care.
    Adebajo A
    BMC Fam Pract; 2012 Mar; 13():23. PubMed ID: 22433164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.
    Bakhriansyah M; Souverein PC; de Boer A; Klungel OH
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1141-1148. PubMed ID: 28370857
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.